BiotechTube
Home/AdjuTec Pharma/Øy
Ø

Øy

Board Chair

AdjuTec Pharma

Therapeutic Areas

Infectious DiseaseAntimicrobial Resistance

AdjuTec Pharma Pipeline

DrugIndicationPhase
APC301Multidrug-resistant bacterial infections (MBL & SBL-producing Enterobacterales)Phase 1
APC302Multidrug-resistant bacterial infectionsPreclinical
APC148-based combinationsOther serious bacterial infectionsResearch
Fungal resistance breakersInvasive fungal diseasesResearch

Leadership Team at AdjuTec Pharma

PR
Pål Rongved
Founder, Professor Emeritus (University of Oslo), Largest Shareholder
View full AdjuTec Pharma profile